65,437 trials
Hepatic Insufficiency · Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant — 58.0; 74.9; 87.6; 46.2 nanograms per milliliter (ng/mL)
Apheresis Related Hypotension
Primary: Rate of Significant Hypotensive Adverse Events — 43; 42 Procedure with a SHAE
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) — 28 Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam — 12.3; 11.4 nanogram*hour per milliliter (ng*hr/mL)
Non-squamous, Non-Small-Cell Lung Cancer · Neoplasms
Primary: Part 1 - Number of Patients With Dose Limiting Toxicity (DLT) Within the First Cycle of Treatment — 1; 0; 0; 1 Participants
Obstructive Sleep Apnea · Snoring
Primary: Adherence to Therapy — 18.4; 26.1 days
Psoriasis
Primary: Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12 — 20.0; 44.0; 50.0; 58.3…
Eosinophilic Esophagitis
Primary: Esophageal Eosinophilia (Number of Eosinophils in the Esophagus) — 5.3 eosinophils/high power field
Early Alzheimer's Disease
Primary: Primary Cognitive Efficacy Endpoint (ADAS-Cog13) — 4.40; 3.89 Score on a scale — p=0.6058
Shoulder Pain
Primary: Shoulder Flexion Passive Range of Movement (PROM) — 153.9; 153.2; 164.5; 165.2 degrees
Cancer Survivors
Primary: Time to Accrual Goal — 9; 9 months
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Hypertension
Primary: Time to Dementia Onset — 22.96; 19.84; 26.82; 25.84 Incidence rate per 1000 person year
Anemia · Iron-deficiency
Primary: Change in Hemoglobin Concentration — 17.7; 12.5; 11.5 g/L
COPD
Primary: Intervention Feasibility — 9.2; 6.4 Sessions